Search Results
You are looking at 1 - 2 of 2 items for
- Author: T. Hansson x
- Refine by access: All content x
Search for other papers by P. Södersten in
Google Scholar
PubMed
Search for other papers by P. Eneroth in
Google Scholar
PubMed
Search for other papers by T. Hansson in
Google Scholar
PubMed
ABSTRACT
Castrated male rats were treated with constant-release implants filled with testosterone, oestradiol-17β, 17β-hydroxy-5α-androstan-3-one (5α-dihydrotestosterone; DHT), 5α-androstane-3α,17β-diol (3α-Adiol) or 5α-androstane-3β,17β-diol (3β-Adiol). Only testosterone activated the sexual behaviour of the rats. If combined with oestradiol, DHT or 3α-Adiol induced the behaviour, but 3β-Adiol failed to have this effect. Oestradiol inhibited the in-vitro formation of [14C]Adiols from [14C]DHT by combined preoptic and hypothalamic tissue, but only when given in high doses. No effect on the formation of [14C]Adiols from [14C]DHT was found in rats treated in vivo with DHT or with the combination of DHT and oestradiol which effectively stimulated sexual behaviour. These results do not support the suggestion that oestradiol may synergize with androgens to induce sexual behaviour in castrated rats by inhibiting androgen metabolism.
J. Endocr. (1988) 119,461–465
Search for other papers by P. Södersten in
Google Scholar
PubMed
Search for other papers by P. Eneroth in
Google Scholar
PubMed
Search for other papers by T. Hansson in
Google Scholar
PubMed
Search for other papers by A. Mode in
Google Scholar
PubMed
Search for other papers by D. Johansson in
Google Scholar
PubMed
Search for other papers by B. Näslund in
Google Scholar
PubMed
Search for other papers by T. Liang in
Google Scholar
PubMed
Search for other papers by J.-Å. Gustafsson in
Google Scholar
PubMed
ABSTRACT
Sexual behaviour was induced in castrated male rats with oestradiol-17β- or testosterone-filled constant-release implants. Testosterone-induced sexual behaviour was unaffected by treatment with the 5α-reductase inhibitor 17β-N,N-diethylcarbamoyl-4-aza-5α-androstan-3-one (4-MA; 16·7 mg/day) but treatment with the aromatization inhibitor 1,4,6-androstatriene-3,17-dione (ATD; 10 mg/day) prevented testosterone from inducing the behaviour. Sexual behaviour could be activated in castrated rats treated with testosterone plus ATD by treatment with 4-MA or with implants filled with a low dose of oestradiol. Lordosis behaviour induced in ovariectomized rats with testosterone-filled implants and progesterone was blocked by ATD treatment and could not be activated with 4-MA but oestradiol implants restored the display of lordosis in the testosterone plus ATD-treated females. 4-MA inhibited the in-vitro formation of [14C]5α-dihydrotestosterone from [14C]testosterone by combined preoptic and hypothalamic tissue at all doses tested and a high dose of oestradiol exerted a similar effect. The results suggest that androgen aromatization is required for testosterone-activated female sexual behaviour but not for testosterone-activated male sexual behaviour. It is suggested that oestradiol normally acts to control the sexual behaviour of male rats by modifying neural androgen metabolism.
J. Endocr. (1986) 111, 455–462
